Praktické lékárenství, 2015, E-verze 6/15
Current pharmacotherapy
Current application of rituximab in pharmacotherapy
Dana Syrová
Prakt. Lékáren. 2015; 11(6e) 
Rituximab is the first registered monoclonal antibody in the treatment of hematologic malignancies. It binds to the surface of B-lymphocytesthat have CD20 antigen on the surface. It was approved by the FDA (Food and Drug Administration) in 1997 for the treatmentof relapsing or refractory follicular lymphoma. The results of further investigations extended its indication to other specialities suchas rheumatology and nephrology. Its introduction in the practice represented a turning point in the treatment and changed the patients’fate, particularly due to its minimal toxicity and higher effect specificity. Targeted monoclonal antibody therapy has...
Recent findings of immunogenetics in relation to the development of serious drug-induced skin reactions
Břetislav Lipový
Prakt. Lékáren. 2015; 11(6e)
Toxická epidermální nekrolýza (TEN) a Stevens-Johnsonův syndrom (SJS) patří do širší skupiny závažných polékových kožních reakcí(SCARs – Severe cutaneous adverse reactions). Do této skupiny patří také DRESS (Drug reaction with eosinophilia and systemic symptoms)a DIHS (Drug induced hypersenzitivity syndrome). V průběhu posledního desetiletí dochází k progresi povědomí o patofyziologické povazejednotlivých syndromů a mechanizmů účinku léků, které k rozvoji těchto stavů vedou. Díky případům nakupení těchto stavů u příbuznýchpacientů se došlo k názoru, že za řadou SCARs může být genetická predispozice (zejména v oblasti hlavního histokopatibilníhokomplexu-MHC)....
Adverse effects of antipsychotic treatment
Ludmila Kameníková, Jan Pomykacz, Hassan Farghali
Prakt. Lékáren. 2015; 11(6e)
The long term use of antipsychotics with several adverse effects is addressed. The article enumerates these adverse effects to emphasizethe importance of thorough treatment according to the overall physical and psychic conditions of the patient with the assessmentof benefit/risk ratio of the given agent.
How will diabetes treatment change with new pharmaceuticals?
Milan Kvapil
Prakt. Lékáren. 2015; 11(6e): e3-e8
Type 2 diabetes mellitus is a heterogeneous disease, with the existing means failing to reach target values of compensation inall patients.Therefore, completely new options for treating hyperglycaemia are beingsought andfound (SGLT2 inhibitors, gliptins, GLP-1receptor agonists). These newpharmaceuticals are at least as effective asolder typesof antidiabetic drugs, but they are certainly safer.Theirkey propertyis minimal riskof hypoglycaemia. They gradually expand the pharmacotherapyoptions for type 2 diabetes andallowfor individual selection and adjustmentof treatment.
PDF of the whole e-version
E-verze 6/15
Prakt. Lékáren. 2015; 11(6e)